FDA Literature Review Requirements for Class III Medical DevicesIntroduction
Why FDA increasingly expects robust literature evidence for Class III devices
For Class III medical devices, the U.S. Food and Drug Administration increasingly expects manufacturers to demonstrate device safety and effectiveness using a totality-of-evidence approach [21 CFR 814.20]. While clinical investigations remain central to Premarket Approval (PMA) pathways, FDA has made it clear that published scientific literature is a critical supporting data source—particularly when assessing long-term safety, post-market performance, and evolving risk profiles [21 CFR 814.20(b)(3)(ii)].
For manufacturers, this shift means that literature reviews are no longer a secondary or informal exercise. FDA expects literature evidence to be systematically identified, critically evaluated, and transparently documented, particularly for high-risk Class III devices [FDA, Scientific Evidence in Medical Device Submissions, Guidance for Industry and FDA Staff (Dec 2017)].
Distinction from EU MDR / CER literature requirements
Although literature reviews are central to EU Medical Device Regulation (MDR) Clinical Evaluation Reports (CERs), FDA expectations differ significantly in both purpose and structure.
EU MDR literature reviews are typically designed to demonstrate conformity with General Safety and Performance Requirements (GSPRs) and to support an ongoing clinical evaluation narrative. In contrast, FDA literature reviews are submission-specific and question-driven, intended to support discrete regulatory decisions such as PMA approvals, post-approval requirements, or labeling changes.
Despite these differences, the core principles of conducting a rigorous EU MDR literature review are broadly applicable across regulatory frameworks.
FDA reviewers place less emphasis on exhaustive narrative summaries and more on whether the literature:
- Directly addresses clearly defined safety or effectiveness questions
- Is methodologically robust and appropriately selected
- Supports—rather than replaces—clinical and post-market evidence
This guide is intended for:
· Regulatory Affairs professionals managing PMA submissions, supplements, and post-approval obligations
· Clinical Affairs teams responsible for evidence generation, surveillance, and indication expansion strategies
· Medical writers and evidence teams conducting FDA-ready literature reviews for Class III devices
It provides practical, FDA-specific guidance on when literature reviews are required, how they are evaluated, and how to design reviews that withstand regulatory scrutiny.
Key Classification Documents:
MDCG 2021-24: Guidance on
classification of medical devices MDCG 2022-5: Guidance on borderline
products MDCG 2019-11: Guidance on
qualification and classification of software
When FDA Requires Literature Reviews
FDA does not prescribe a single, standardized literature review format. Instead, literature evidence is expected in defined regulatory contexts where published data can meaningfully inform safety, effectiveness, or ongoing risk assessment.
PMA submissions and PMA supplements
Literature reviews are commonly included as supportive evidence in Premarket Approval (PMA) submissions, particularly when:
- The device technology has prior clinical use or published evidence
- Comparable or related technologies have established safety or performance data
- Long-term outcomes extend beyond the duration of pivotal clinical studies
For PMA supplements—including design changes, manufacturing modifications, or labeling updates—the FDA may expect updated literature searches to confirm that new evidence does not materially impact the established benefit–risk profile
[21 CFR 814.39].
522 Postmarket Surveillance Studies
Under Section 522 of the Federal Food, Drug, and Cosmetic Act, FDA may require manufacturers to conduct postmarket surveillance studies to address specific safety or effectiveness concerns [21 U.S.C. § 360l; 21 CFR Part 822].
In this context, literature reviews may support:
- Background risk assessments
- Identification of known or emerging adverse events
- Justification of study design, endpoints, or duration
For higher-risk Class III devices, ongoing literature monitoring may form part of broader postmarket surveillance and lifecycle compliance expectations.
Indication expansion and label changes
When manufacturers seek expanded indications for use or labeling modifications, published studies may supplement new clinical data [21 CFR 814.39].
Literature may help:
- Demonstrate clinical experience in broader or adjacent patient populations
- Support biological or mechanistic plausibility
- Contextualize outcomes relative to existing approved indications
However, FDA evaluates whether the literature is sufficiently device-specific and methodologically robust. Where proposed indications introduce new risks or substantially different patient populations, literature is expected to supplement — not replace — new clinical investigations.
Annual reports and post-approval obligations
For approved Class III devices, FDA may expect literature evidence as part of annual reports or post-approval study updates [21 CFR 814.84].
These reviews support ongoing safety surveillance by identifying:
- Newly published adverse events
- Shifts in clinical practice or device utilization
- Emerging comparative effectiveness data
Real-world evidence expectations
FDA’s authority to incorporate real-world evidence (RWE) into regulatory decision-making was reinforced under the 21st Century Cures Act [21st Century Cures Act § 3022]. Subsequent FDA guidance further clarifies expectations for relevance, reliability, and methodological rigor when real-world evidence is used to support regulatory decisions.
For Class III devices, manufacturers are expected to critically appraise published real-world data and clearly articulate how it informs regulatory decision-making within the context of safety and effectiveness.
Screening and Study Selection
Manufacturers should describe:
- The literature screening process and selection criteria applied
- The rationale for excluding identified studies
- The methodology used to determine final study inclusion
PRISMA-style flow diagrams can be useful for transparently illustrating the study selection process, particularly when literature constitutes a significant component of the regulatory evidence package.
Critical Appraisal and Regulatory Relevance
In the FDA context, critical appraisal emphasizes regulatory relevance rather than purely academic critique.
Manufacturers should assess:
- Study design, including potential sources of bias
- The relevance of study endpoints to the device’s intended use
- The applicability of findings to the indicated or proposed patient population
The objective is not to provide a descriptive summary of the literature, but to determine whether the published evidence meaningfully supports the specific regulatory question being addressed.
Synthesis and Gap Analysis
Literature findings should be synthesized to directly address defined safety and effectiveness questions.
Where evidence gaps are identified, manufacturers should:
- Acknowledge and characterize the limitations of the available evidence
- Justify why the existing evidence remains sufficient, where applicable
- Identify additional data sources used to address or mitigate residual uncertainty
This structured approach enhances regulatory defensibility and reduces the risk of review deficiencies.
PRISMA alignment for FDA submissions
Although PRISMA was developed for academic systematic reviews, its transparency principles are often useful in FDA regulatory contexts when literature plays a significant evidentiary role.
Structured reporting elements — such as documented screening steps, clear inclusion and exclusion criteria, and flow diagrams summarizing study selection — can enhance methodological clarity and reduce ambiguity during FDA review.
Importantly, FDA does not require academic publication formatting. However, applying PRISMA-aligned principles can strengthen transparency and reproducibility when literature serves as a substantive component of the regulatory evidence package.
Screening and selection process
FDA expects manufacturers to clearly describe the processes used to screen and select studies. This includes:
- Predefined inclusion and exclusion criteria
- The rationale for excluding identified studies
- Documentation of screening decisions (e.g., PRISMA-aligned reporting)
PRISMA-style flow diagrams are often useful for transparently illustrating the study selection process, even when a fully systematic review is not required.
Critical appraisal in an FDA context
Critical appraisal should focus on regulatory relevance, rather than academic critique alone. FDA reviewers are primarily concerned with whether study limitations affect the reliability of conclusions related to safety and effectiveness.
Manufacturers should assess:
- Study design, including potential sources of bias
- The relevance of study outcomes to the device’s intended use
- The applicability of findings to the approved or proposed indication
Synthesis and gap analysis
Literature findings should be synthesized to answer specific regulatory questions, rather than summarized descriptively. Identified gaps should be acknowledged and addressed through additional data sources where appropriate.
How Evidence Cloud Supports FDA Literature Requirements
Developing FDA-ready literature reviews requires tools that support traceability, transparency, and continuous updating. Platforms such as Evidence Cloud are designed to align with these regulatory expectations, enabling consistent and scalable literature workflows.
Key capabilities include:
- Multi-database search management, enabling structured and reproducible search strategies
- Audit trails documenting search strategies, screening decisions, and subsequent updates
- Living review functionality to support ongoing post-market surveillance (PMS) and post-approval requirements
These capabilities help regulatory and clinical teams maintain consistent, inspection-ready literature processes across the device lifecycle.
Conclusion
Key takeaways
For Class III medical devices, literature reviews are an increasingly important component of FDA regulatory strategy. They support:
- Premarket Approval (PMA) submissions and supplements
- Postmarket surveillance activities, including 522 study requirements
- Indication expansions and labeling updates
FDA expects literature evidence to be purpose-driven, methodologically sound, and transparently documented to support regulatory decision-making.
Moving toward standardized, FDA-ready processes
By aligning literature review workflows with FDA expectations—rather than repurposing EU MDR methodologies—manufacturers can reduce regulatory friction and improve evidence quality across submissions.
Standardized processes, supported by appropriate tools and documentation practices, help ensure that literature evidence remains current, defensible, and actionable throughout the product lifecycle.
As FDA continues to emphasize real-world performance and lifecycle oversight, literature reviews will remain a foundational element of Class III regulatory strategy.
Optional companion resources
Manufacturers may benefit from developing internal tools such as:
- An FDA literature review checklist
- Standard operating procedures (SOPs) for postmarket surveillance (PMS) literature monitoring
- Templates for evidence summaries supporting indication expansions
These resources can help strengthen regulatory readiness and improve cross-functional consistency in literature review processes.
FDA-Specific Literature Review Requirements
Applicable FDA guidance documents
FDA does not issue a single guidance dedicated exclusively to literature reviews. Instead, expectations are embedded across guidances addressing scientific evidence, PMA submissions, post-approval studies, and real-world evidence.
Notably, the FDA guidance Scientific Evidence in Medical Device Submissions (2017) outlines principles for evaluating the relevance, reliability, and methodological quality of published data submitted in support of regulatory decisions.
Together, these documents establish that literature evidence must be:
- Relevant to the regulatory question
- Scientifically valid and methodologically sound
- Transparently documented and reproducible.
Systematic vs. targeted literature reviews
FDA does not require all literature reviews to follow a fully systematic methodology. The level of rigor depends on the regulatory context and the role literature plays in the evidence package.
Systematic literature reviews are most appropriate when:
- When literature serves as a primary evidence source
- When supporting indication expansion
- When evaluating long-term safety or rare adverse events
In such cases, predefined inclusion criteria, structured screening, and transparent documentation are expected. PRISMA-aligned principles are commonly used to demonstrate methodological rigor.
Targeted literature reviews may be appropriate for focused updates, such as confirming the absence of newly reported adverse events or updating prior submissions.
Regardless of approach, manufacturers should justify the selected methodology based on the regulatory objective.
Search strategy documentation expectations
FDA places significant emphasis on transparency and reproducibility of search methodology.
Literature reviews submitted in regulatory contexts should clearly document:
- Databases searched
- Date ranges covered
- Complete search strings and Boolean logic
- Inclusion and exclusion criteria
Clear documentation allows FDA reviewers to assess whether the search was appropriately comprehensive and relevant to the regulatory question.
Literature for Post-Market Surveillance (Deep Dive)
Ongoing safety monitoring through published literature
For Class III medical devices, postmarket surveillance (PMS) extends beyond formal adverse event reporting systems and post-approval studies. The FDA expects manufacturers to actively monitor published scientific literature as part of ongoing safety oversight.
Peer-reviewed publications can identify emerging safety signals that may not yet be evident through internal complaint handling or Medical Device Reporting (MDR) systems. These may include:
- Delayed or cumulative adverse events
- Rare complications associated with broader clinical use
- Device interactions identified in real-world settings
As a result, literature monitoring is increasingly viewed by the FDA as a proactive risk management activity rather than a retrospective documentation exercise.
Signal detection from published adverse events
One of the primary regulatory purposes of postmarket literature review is signal detection. Case reports, case series, observational studies, and registry publications may describe adverse events that warrant further evaluation, even when event rates are low or causality is uncertain.
FDA expects manufacturers to demonstrate that they:
- Routinely screen the literature for device-related adverse events
- Assess the clinical relevance and plausibility of identified signals
- Escalate credible signals through established internal risk management processes
The FDA does not expect every published adverse event to result in regulatory action. However, manufacturers should document how literature-based signals are evaluated, trended, and resolved, including justification when no further action is required.
Integrating literature with MDR and complaint data
Literature findings should not be evaluated in isolation. The FDA expects manufacturers to integrate published evidence with internal data sources, including:
- MDR submissions
- Complaint handling records
- Post-approval or postmarket study data
This integrated approach enables manufacturers to assess whether signals identified in the literature are consistent with internal experience or indicative of emerging risks.
For example, a complication reported sporadically in published case series may carry greater significance if similar events are observed in complaint data. Conversely, literature-reported events that are not corroborated internally may still require documentation and a rationale explaining their relevance (or lack thereof) to the device’s approved use.
Frequency and update expectations
The FDA does not prescribe a fixed frequency for literature review updates across all Class III medical devices. Instead, expectations are risk-based and context-dependent.
Factors influencing review frequency include:
- Device risk profile and intended use
- Severity and reversibility of potential adverse events
- Extent of real-world use and market penetration
- Post-approval study obligations, including 522 study requirements
Literature Supporting Indication Expansion
Building evidence packages from published studies
When manufacturers seek expanded indications for use, literature reviews often play a critical role in supporting the regulatory rationale. The FDA expects literature evidence to contribute to a coherent evidence package rather than serve as a standalone justification.
Published studies may be used to:
- Demonstrate clinical experience in broader or adjacent patient populations
- Support biological or mechanistic plausibility for the expanded use
- Provide long-term or real-world outcomes not captured in clinical trials
In this context, FDA evaluates literature based on relevance, quality, and applicability to the proposed indication, with particular attention to alignment of patient populations and clinical endpoints.
Handling off-label use literature
Literature describing off-label use can be informative but requires careful interpretation. The FDA generally permits consideration of off-label literature as contextual evidence, provided manufacturers clearly distinguish:
- Approved versus unapproved use scenarios
- Differences in patient populations, dosing, or procedural technique
- Limitations related to study design, intent, or generalizability [21 CFR 814.39]
Manufacturers should avoid overstating conclusions drawn from off-label studies and should clearly explain how such data supports—without replacing—the required clinical evidence.
Comparator device literature strategies
In some indication expansion cases, direct device-specific literature may be limited. The FDA may allow manufacturers to reference comparator or similar device literature to contextualize expected performance or risk profiles.
When using comparator literature, manufacturers should justify:
- Technological similarity and alignment of intended use
- Differences in materials, design, or mechanism of action
- Relevance of reported outcomes to the subject device
A clear scientific rationale is essential to avoid inappropriate extrapolation of findings.
When literature alone is insufficient
FDA generally does not accept literature evidence as the sole basis for indication expansion when:
- The proposed indication introduces new risks
- Patient populations differ substantially from those previously studied
- Outcomes are subjective or highly operator-dependent
In these scenarios, literature is expected to supplement, not replace, new clinical investigations.
Practical Workflow: Conducting FDA-Ready Literature Reviews
Database selection
FDA expects literature reviews to be conducted using appropriate and comprehensive databases, selected based on the clinical and regulatory question being addressed.
Commonly used sources include:
- PubMed / MEDLINE
- Embase
- FDA databases and advisory committee materials
Manufacturers should justify database selection and demonstrate that key sources relevant to the device and indication were included.
Search string documentation
earch strategies should be predefined, documented, and reproducible. FDA reviewers may assess whether search terms were sufficiently sensitive to capture relevant evidence. [FDA, Scientific Evidence in Medical Device Submissions (Dec 2017)]
Documentation typically includes:
- Full search strings and Boolean operators
- Date ranges
- Filters or limits applied
Well-documented searches reduce ambiguity and support regulatory confidence.
Latest Articles
ATTNs Ethan Glasser Dover, Delaware, 19901, United States
